CIRM Funded Clinical Trials

Clinical Study to Assess Safety and Efficacy of Subretinal Injection of Human Neural Progenitor Cells for Treatment of Retinitis Pigmentosa


Clive Svendsen
Disease Area: 
Investigator:
CIRM Grant:
CLIN2-11620 (Pre-Active)
Award Value:
$10,444,063
Trial Sponsor:
Cedars-Sinai Medical Center
Trial Stage: 
Phase 1
Trial Status: 
Launching
Targeted Enrollment:
N/A
Details: 

Retinitis pigmentosa is a blinding eye disease that affects approximately 150,000 individuals in the US and 1.5 million people around the world. It is caused by the destruction of light-sensing cells in the back of the eye known as photoreceptors.  This leads to gradual vision loss and eventually blindness.

For this trial, human neural progenitor cells (hNPCs) are transplanted to the back of the eye of retinitis pigmentosa patients. The goal is that the transplanted hNPCs will integrate and create a protective layer of cells that prevent destruction of the adjacent photoreceptors. 

Design: 

This is a Phase 1 study.

Goal: 

To evaluate safety and preliminary efficacy.